GBM
MCID: GLB015
MIFTS: 75

Glioblastoma Multiforme (GBM)

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 74 52 58 29 54 6 15 17 71
Glioblastoma 52 58 29 54 6 43 71
Gbm 12 58
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 71
Adult Glioblastoma 71

Characteristics:

Orphanet epidemiological data:

58
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3068
MeSH 43 D005909
SNOMED-CT 67 63634009
MESH via Orphanet 44 D005909
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0017636 C1621958
Orphanet 58 ORPHA360
UMLS 71 C0017636 C0278878 C1514422 more

Summaries for Glioblastoma Multiforme

NIH Rare Diseases : 52 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1 , Turcot syndrome and Li Fraumeni syndrome . There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy .

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to glioma susceptibility 1 and giant cell glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma Multiforme is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Class I MHC mediated antigen processing and presentation. The drugs Dabrafenib and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are seizures and muscle weakness

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Wikipedia : 74 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1081)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 34.8 TP53 PTEN PMS2 PIK3CA NRAS MTOR
2 giant cell glioblastoma 34.5 TP53 PTEN IDH1 FGFR1 EGFR BRAF
3 glioma 34.3 TP53 PTEN PIK3CA MIR221 MIR210 MIR21
4 mismatch repair cancer syndrome 33.8 PTEN PMS2 MSH2
5 glial tumor 33.1 PTEN IDH1
6 grade iii astrocytoma 32.9 TP53 PTEN IDH1 EGFR
7 meningioma, familial 32.8 TP53 PTEN PIK3CA IDH1 EGFR
8 brain cancer 32.7 TP53 PTEN PMS2 PIK3CA NRAS MSH2
9 gliosarcoma 32.5 TP53 PTEN IDH1 FGFR1 EGFR
10 medulloblastoma 32.4 TP53 PTEN PIK3CA NRAS MTOR MSH2
11 myeloma, multiple 32.3 TP53 PTEN NRAS MTOR MIR21 IDH1
12 brain glioma 32.3 TP53 PTEN IDH1 EGFR
13 neuroblastoma 32.3 TP53 PTEN PIK3CA NRAS MTOR MSH2
14 gliomatosis cerebri 32.2 TP53 PTEN IDH1 EGFR BRAF
15 oligodendroglioma 32.2 TP53 PTEN PMS2 MSH2 IDH1 FGFR1
16 lung cancer susceptibility 3 32.2 TP53 PTEN PIK3CA NRAS MTOR MIR21
17 adenocarcinoma 32.1 TP53 PTEN PIK3CA MSH2 HRAS FGFR1
18 fibrillary astrocytoma 32.1 TP53 PTEN IDH1 EGFR
19 exanthem 32.1 MTOR HRAS EGFR
20 mixed glioma 32.0 TP53 PTEN IDH1 EGFR
21 pleomorphic xanthoastrocytoma 32.0 TP53 IDH1 BRAF
22 gastric adenocarcinoma 31.9 TP53 PTEN PIK3CA NRAS MTOR IDH1
23 adenoma 31.9 TP53 PIK3CA MSH2 BRAF
24 neurofibromatosis, type ii 31.9 TP53 PTEN MTOR HRAS EGFR
25 lymphoma 31.9 TP53 PMS2 PIK3CA NRAS MSH2 FGFR1
26 sarcoma 31.9 TP53 PIK3CA NRAS MTOR MSH2 HRAS
27 tuberous sclerosis 31.8 TP53 PTEN PIK3CA MTOR
28 thyroid gland cancer 31.8 TP53 PTEN PIK3CA NRAS MIR221 HRAS
29 thyroid carcinoma 31.8 PTEN PIK3CA HRAS BRAF
30 squamous cell carcinoma 31.8 TP53 PTEN PIK3CA HRAS EGFR BRAF
31 ganglioglioma 31.7 TP53 IDH1 BRAF
32 gemistocytic astrocytoma 31.7 TP53 PTEN IDH1
33 brain stem glioma 31.7 TP53 PTEN PIK3CA IDH1 FGFR1 EGFR
34 bladder cancer 31.7 TP53 PTEN PIK3CA NRAS MIR221 MIR21
35 leukemia, chronic lymphocytic 31.7 TP53 PTEN PIK3CA NRAS MIR221 MIR21
36 li-fraumeni syndrome 31.7 TP53 PTEN PMS2 MSH2 IDH1 HRAS
37 rhabdomyosarcoma 31.6 TP53 PTEN PMS2 MTOR MSH2 HRAS
38 melanoma 31.6 TP53 PTEN PIK3CA NRAS MTOR MIR221
39 breast adenocarcinoma 31.6 TP53 PIK3CA MTOR IDH1 EGFR
40 retinitis pigmentosa 11 31.6 TP53 PTEN HRAS EGFR
41 leukemia, chronic myeloid 31.5 TP53 PTEN NRAS HRAS FGFR1 EGFR
42 small cell cancer of the lung 31.5 TP53 PTEN PIK3CA MIR21 EGFR
43 cholangiocarcinoma 31.5 TP53 PIK3CA MTOR MIR21 IDH1 EGFR
44 hemangioma 31.5 TP53 PTEN MTOR IDH1
45 small cell carcinoma 31.5 TP53 PTEN EGFR
46 spitz nevus 31.5 TP53 HRAS BRAF
47 malignant ependymoma 31.5 TP53 IDH1 EGFR
48 lynch syndrome 31.5 TP53 PTEN PMS2 PIK3CA MSH2 HRAS
49 supratentorial cancer 31.5 TP53 IDH1 EGFR
50 central nervous system cancer 31.4 TP53 PTEN MIR21 MIR155 MIR149 IDH1

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

Human phenotypes related to Glioblastoma Multiforme:

58 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 58 Occasional (29-5%)
2 muscle weakness 58 Frequent (79-30%)
3 fatigue 58 Frequent (79-30%)
4 memory impairment 58 Occasional (29-5%)
5 headache 58 Frequent (79-30%)
6 visual loss 58 Frequent (79-30%)
7 abnormality of the cerebral white matter 58 Frequent (79-30%)
8 paralysis 58 Frequent (79-30%)
9 abnormal corpus callosum morphology 58 Frequent (79-30%)
10 language impairment 58 Frequent (79-30%)
11 cerebral edema 58 Frequent (79-30%)
12 abnormality of nervous system physiology 58 Frequent (79-30%)
13 mood changes 58 Frequent (79-30%)
14 glioblastoma 58 Obligate (100%)
15 abnormal cell morphology 58 Very frequent (99-80%)

UMLS symptoms related to Glioblastoma Multiforme:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.38 EGFR HRAS MTOR PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.38 EGFR HRAS MTOR PIK3CA BRAF
3 Decreased viability GR00221-A-1 10.38 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
4 Decreased viability GR00221-A-2 10.38 FGFR1 HRAS PIK3CA
5 Decreased viability GR00221-A-3 10.38 HRAS NRAS
6 Decreased viability GR00221-A-4 10.38 EGFR MTOR PIK3CA BRAF
7 Decreased viability GR00249-S 10.38 BRAF
8 Decreased viability GR00301-A 10.38 BRAF
9 Decreased viability GR00342-S-1 10.38 MTOR
10 Decreased viability GR00342-S-2 10.38 MTOR
11 Decreased viability GR00381-A-1 10.38 BRAF
12 Decreased viability GR00386-A-1 10.38 FGFR1
13 Decreased viability GR00402-S-2 10.38 PIK3CA
14 Decreased cell migration GR00055-A-3 9.85 BRAF EGFR HRAS MTOR PIK3CA
15 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
16 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
17 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 BCOR BRAF EGFR FGFR1 HRAS MTOR
2 digestive/alimentary MP:0005381 10.11 BRAF EGFR FGFR1 HRAS MSH2 NRAS
3 hematopoietic system MP:0005397 10.11 BCOR BRAF EGFR FGFR1 IDH1 MSH2
4 endocrine/exocrine gland MP:0005379 10.1 BRAF EGFR FGFR1 HRAS MTOR NRAS
5 immune system MP:0005387 10.1 BCOR BRAF EGFR FGFR1 IDH1 MSH2
6 embryo MP:0005380 10.09 BCOR BRAF EGFR FGFR1 MTOR NRAS
7 integument MP:0010771 9.91 BRAF EGFR FGFR1 HRAS MSH2 NRAS
8 neoplasm MP:0002006 9.81 BRAF EGFR HRAS MSH2 NRAS PIK3CA
9 no phenotypic analysis MP:0003012 9.5 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
10 skeleton MP:0005390 9.32 BRAF EGFR FGFR1 HRAS IDH1 MTOR

Drugs & Therapeutics for Glioblastoma Multiforme

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 572)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
6
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Trioxsalen Approved Phase 3 3902-71-4 5585
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Streptozocin Approved, Investigational Phase 2, Phase 3 18883-66-4 29327
13
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
14
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
15
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
16
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
17
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
18
Gemcitabine Approved Phase 3 95058-81-4 60750
19
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
20
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
21
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
22
Bevacizumab Approved, Investigational Phase 3 216974-75-3
23
Iodine Approved, Investigational Phase 3 7553-56-2 807
24
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
25
Etoposide Approved Phase 3 33419-42-0 36462
26
Povidone-iodine Approved Phase 3 25655-41-8
27
Povidone Approved Phase 3 9003-39-8
28
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
29
nivolumab Approved Phase 2, Phase 3 946414-94-4
30
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
31
Carmustine Approved, Investigational Phase 3 154-93-8 2578
32
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
33
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
34
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
35
Histamine Approved, Investigational Phase 3 51-45-6 774
36
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
37
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
38
Norepinephrine Approved Phase 3 51-41-2 439260
39
Cyproheptadine Approved Phase 3 129-03-3 2913
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
41
Nimotuzumab Investigational Phase 3 828933-61-3, 780758-10-3
42
Rindopepimut Investigational Phase 3 1108208-65-6
43 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
44
Semustine Experimental, Investigational Phase 2, Phase 3 13909-09-6
45
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
46 Dianhydrogalactitol Investigational Phase 3 23261-20-3
47 Interferon-alpha Phase 3
48 Vasoconstrictor Agents Phase 3
49 Ophthalmic Solutions Phase 3
50 Dihematoporphyrin Ether Phase 3

Interventional clinical trials:

(show top 50) (show all 1633)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
5 Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma Unknown status NCT01290939 Phase 3 lomustine
6 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
7 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
8 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
9 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
10 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
11 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
12 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
13 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
14 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
15 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
16 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
17 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
18 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
19 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
20 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
21 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
22 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
23 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
24 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
25 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
26 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
27 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
28 Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) Completed NCT03419403 Phase 3 Steroid eye drop;Ophthalmic steroid ointment;Temozolomide;depatuxizumab mafodotin;Vasoconstrictor eye drop
29 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
30 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
31 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
32 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
33 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
34 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
35 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
36 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
37 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
38 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
39 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
40 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
41 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
42 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Completed NCT01805453 Phase 3 Losartan;Placebo
43 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
44 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
45 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
46 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
47 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
48 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
49 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
50 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Genetic tests related to Glioblastoma Multiforme:

# Genetic test Affiliating Genes
1 Glioblastoma 29
2 Glioblastoma Multiforme 29

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

40
Brain, T Cells, Endothelial, Testes, Lung, Breast, Spinal Cord

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 31079)
# Title Authors PMID Year
1
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 46 54 61
18577219 2008
2
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. 46 61
19559015 2009
3
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). 46 61
18759060 2009
4
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
5
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
6
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
7
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 61 54
19937796 2010
8
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. 61 54
20428809 2010
9
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. 54 61
20467331 2010
10
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. 54 61
20195615 2010
11
FasL gene knock-down therapy enhances the antiglioma immune response. 54 61
20406899 2010
12
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. 61 54
20412570 2010
13
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. 54 61
20462843 2010
14
Promising human brain tumors therapy with interference RNA intervention (iRNAi). 54 61
20118657 2010
15
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. 61 54
20127563 2010
16
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. 54 61
20150365 2010
17
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. 61 54
20150362 2010
18
Evaluation of the prognostic value of CD44 in glioblastoma multiforme. 61 54
20150644 2010
19
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. 54 61
19931733 2009
20
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. 61 54
19996278 2009
21
Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. 54 61
19861406 2009
22
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. 54 61
19164435 2009
23
STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. 54 61
19658181 2009
24
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. 61 54
19637364 2009
25
A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. 54 61
19808964 2009
26
Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. 61 54
19723667 2009
27
Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. 61 54
19996130 2009
28
The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. 54 61
19601750 2009
29
MGMT promoter hypermethylation in a series of 104 glioblastomas. 54 61
19656999 2009
30
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. 54 61
18952979 2009
31
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. 61 54
19412429 2009
32
Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas. 54 61
19587465 2009
33
Activation of telomerase by human cytomegalovirus. 54 61
19318640 2009
34
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 61 54
19346643 2009
35
Tyrosine phosphorylation and CD95: a FAScinating switch. 61 54
19221505 2009
36
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. 61 54
19011762 2009
37
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. 61 54
19293809 2009
38
Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. 54 61
19074142 2009
39
Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. 54 61
19141386 2009
40
Significance of p53 and CD31 in astrogliomas. 61 54
18821037 2009
41
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. 61 54
19657395 2009
42
The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. 61 54
18991494 2009
43
Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. 54 61
18940813 2008
44
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. 61 54
18955445 2008
45
Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib. 61 54
19189656 2008
46
The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. 61 54
18976073 2008
47
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. 61 54
18400046 2008
48
Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44. 61 54
19024103 2008
49
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. 54 61
18757412 2008
50
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. 61 54
18665158 2008

Variations for Glioblastoma Multiforme

ClinVar genetic disease variations for Glioblastoma Multiforme:

6 (show top 50) (show all 231) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 H3-3A NM_002107.6(H3-3A):c.103G>A (p.Gly35Arg)SNV other 438766 rs1553260624 1:226252155-226252155 1:226064454-226064454
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp)SNV other 438772 rs1556339256 X:70357729-70357729 X:71137879-71137879
3 MSH2 NM_000251.2(MSH2):c.1958_1965del (p.Asn653fs)deletion Pathogenic 590849 rs1558518449 2:47702360-47702367 2:47475221-47475228
4 PTEN NM_000314.7(PTEN):c.697C>T (p.Arg233Ter)SNV Pathogenic 7813 rs121909219 10:89717672-89717672 10:87957915-87957915
5 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
6 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
7 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
8 TP53 NM_001126112.2(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
9 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
10 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
11 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
12 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
13 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
14 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
15 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
16 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
17 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
18 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
19 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
20 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
21 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu)SNV Pathogenic,drug response 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
22 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
23 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val)SNV Pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
24 EGFR NM_005228.5(EGFR):c.2156G>C (p.Gly719Ala)SNV Pathogenic 45225 rs121913428 7:55241708-55241708 7:55174015-55174015
25 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
26 PMS2 NM_000535.7(PMS2):c.1831dup (p.Ile611fs)duplication Pathogenic 91317 rs63750250 7:6026564-6026565 7:5986933-5986934
27 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
28 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
29 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
30 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
31 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro)SNV Pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
32 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
33 MTOR NM_004958.4(MTOR):c.4448G>T (p.Cys1483Phe)SNV Pathogenic 190121 rs786205165 1:11217230-11217230 1:11157173-11157173
34 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
35 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
36 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
37 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
38 BCOR NM_001123385.2(BCOR):c.3881_3882AG[1] (p.Leu1296fs)short repeat Pathogenic 284290 rs886042842 X:39922288-39922289 X:40063035-40063036
39 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
40 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
41 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys)SNV Pathogenic 376050 rs121913284 3:178921553-178921553 3:179203765-179203765
42 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
43 TP53 NM_001126112.2(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
44 TP53 NM_001126112.2(TP53):c.713G>C (p.Cys238Ser)SNV Pathogenic 376575 rs730882005 17:7577568-7577568 17:7674250-7674250
45 TP53 NM_001126112.2(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
46 TP53 NM_001126112.2(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
47 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
48 TP53 NM_001126112.2(TP53):c.730G>A (p.Gly244Ser)SNV Pathogenic 376600 rs1057519989 17:7577551-7577551 17:7674233-7674233
49 TP53 NM_001126112.2(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
50 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000 Gain Glioblastoma multiforme
30 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
31 25428 1 189000000 197500000 Gain Glioblastoma multiforme
32 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
33 26137 1 197500000 205300000 Amplification LRRN5 Glioblastoma multiforme
34 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
35 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
37 26146 1 197500000 205300000 Amplificationlication HDMX Glioblastoma multiforme
38 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
39 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
40 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
41 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
42 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
43 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
44 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
45 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
46 31747 1 30500000 171200000 Gain Glioblastoma multiforme
47 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
48 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
49 32900 1 4028404 6333694 Deletion CHD5 Glioblastoma multiforme
50 33876 1 4952248 20897624 Deletion CDC42 Glioblastoma multiforme

Expression for Glioblastoma Multiforme

Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for Glioblastoma Multiforme

Pathways related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 TP53 PIK3CA NRAS MTOR HRAS FGFR1
2
Show member pathways
13.54 TP53 PTEN PIK3CA NRAS MTOR HRAS
3
Show member pathways
13.43 TP53 PIK3CA NRAS HRAS FGFR1 EGFR
4
Show member pathways
13.3 TP53 PTEN NRAS MTOR HRAS EGFR
5
Show member pathways
13.19 TP53 PTEN PIK3CA MTOR FGFR1 EGFR
6
Show member pathways
13.18 TP53 PTEN NRAS MTOR HRAS FGFR1
7
Show member pathways
13.16 TP53 PTEN PIK3CA NRAS MTOR HRAS
8
Show member pathways
13.14 TP53 PIK3CA NRAS HRAS EGFR BRAF
9
Show member pathways
13.1 TP53 PTEN PIK3CA NRAS MTOR HRAS
10
Show member pathways
13.03 TP53 PIK3CA NRAS MTOR HRAS EGFR
11
Show member pathways
13.02 PTEN PIK3CA NRAS MTOR HRAS EGFR
12
Show member pathways
12.99 PTEN PIK3CA NRAS HRAS EGFR BRAF
13
Show member pathways
12.97 PTEN PIK3CA NRAS MTOR HRAS FGFR1
14
Show member pathways
12.92 PIK3CA NRAS HRAS EGFR BRAF
15
Show member pathways
12.88 TP53 PTEN PIK3CA NRAS MTOR MSH2
16 12.87 TP53 NRAS HRAS FGFR1 EGFR BRAF
17
Show member pathways
12.85 PTEN PIK3CA MTOR HRAS BRAF
18
Show member pathways
12.84 PIK3CA NRAS HRAS FGFR1 EGFR BRAF
19
Show member pathways
12.83 TP53 PTEN PIK3CA NRAS MTOR HRAS
20
Show member pathways
12.8 TP53 PTEN PIK3CA NRAS MTOR HRAS
21
Show member pathways
12.79 TP53 PTEN PIK3CA NRAS MTOR HRAS
22 12.79 TP53 PTEN PIK3CA NRAS MTOR MSH2
23
Show member pathways
12.76 PIK3CA NRAS MTOR HRAS EGFR
24
Show member pathways
12.75 TP53 NRAS HRAS EGFR BRAF
25 12.75 PIK3CA NRAS HRAS FGFR1 EGFR BRAF
26
Show member pathways
12.73 PIK3CA NRAS MTOR HRAS EGFR
27
Show member pathways
12.72 PTEN PIK3CA NRAS MTOR HRAS EGFR
28
Show member pathways
12.71 TP53 PIK3CA NRAS MSH2 HRAS EGFR
29
Show member pathways
12.71 TP53 PTEN PIK3CA NRAS MTOR HRAS
30
Show member pathways
12.68 TP53 PTEN PIK3CA NRAS MTOR HRAS
31
Show member pathways
12.66 PIK3CA NRAS HRAS FGFR1 BRAF
32
Show member pathways
12.59 PTEN PIK3CA NRAS MTOR HRAS
33
Show member pathways
12.56 PTEN PIK3CA NRAS MTOR HRAS
34
Show member pathways
12.56 TP53 PTEN PIK3CA NRAS MTOR HRAS
35
Show member pathways
12.55 PIK3CA NRAS MTOR HRAS EGFR
36
Show member pathways
12.52 PTEN PIK3CA NRAS HRAS BRAF
37
Show member pathways
12.52 PIK3CA NRAS MTOR HRAS FGFR1 EGFR
38
Show member pathways
12.52 TP53 PIK3CA NRAS MTOR HRAS FGFR1
39